Class 2 vs 3 variants are noted in melanoma (11.3% vs 9.4%), CRC (5.6% vs 15.2%), and NSCLC (20.8% vs 19.1%), which commonly carry BRAF variants.10 This evidence concerns the gene BRAF and melanoma.